Open main menu

HemOnc.org - A Hematology Oncology Wiki β

Cutaneous T-cell lymphoma - null regimens

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main CTCL page for current regimens.


Contents

Relapsed or refractory

Placebo

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Prince et al. 2010 (L4389-11) NR Phase III (C) Denileukin diftitox Inferior PFS

References

  1. L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains verified protocol PubMed